In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 28th, 2005 | 43 | No |
Popular Name: Dihydroergotamine mesylate Dihydroergotamine mesylate
(10alphaH)-5'alpha-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman
(5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
(5'alpha)-5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxoergotaman
5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman
511-12-6; C07798; Dihydroergotamine
5989-77-5; D07838; Dihydroergotamine tartrate; Divegal (TN)
8067-24-1; Dihydroergotoxine mesylate; Prestwick_746
9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione
Dihidroergotamina [INN-Spanish]
dihidroergotamina; dihydroergotamine; dihydroergotaminum
Dihydroergotamine methanesulfonate
Dihydroergotamine monomethanesulfonate
Dihydroergotaminum [INN-Latin]
Ergoloid Mesylates (dihydroergotoxine)
Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)-
Ergotamine, dihydro, methanesulfonate (salt)
INN); Dihydroergotamine Mesilate (JAN); Dihydroergotamine Mesylate (FDA
INN); Dihydroergotamine Mesylate (FDA
USAN); Dihydroergotamine Mesilate (JAN)
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.09 | -6.7 | -65.06 | 4 | 10 | 1 | 119 | 584.697 | 4 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 2.29e-01 g/l | DrugBank-approved |
UniProt Database Links | EASG_CLAP2; EASG_CLAPU; OAR_DROME | ChEBI |
PUBCHEM_PATENT_ID | EP0000682A1; EP0001115A2; EP0001368A1; EP0001924A1; EP0001924B2; EP0002991A1; EP0005101A1; EP0005646A1; EP0006040A2; EP0006435A1; EP0010036A1; EP0010200A1; EP0010405A1; EP0011536A2; EP0011595A1; EP0011935A2; EP0011935B2; EP0014165A1; EP0014663A1; EP001521 | IBM Patent Data |
Therapy | Ergot alkaloid; vasoconstrictor; competitive serotonin receptor antagonist; partial agonist at alpha adrenoceptors and D | SMDC MicroSource |
PUBCHEM_PATENT_ID | US4457907 | IBM Patent Data |
therap | vasoconstrictor, antimigraine | MicroSource Spectrum |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
ADA2A-1-E | Alpha-2a Adrenergic Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 4 | 0.27 | Binding ≤ 10μM |
ADA2B-1-E | Alpha-2b Adrenergic Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 4 | 0.27 | Binding ≤ 10μM |
ADA2C-1-E | Alpha-2c Adrenergic Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 4 | 0.27 | Binding ≤ 10μM |
CP3A4-2-E | Cytochrome P450 3A4 (cluster #2 Of 4), Eukaryotic | Eukaryotes | 2999 | 0.18 | ADME/T ≤ 10μM |
Z104304-1-O | Adrenergic Receptor Alpha-1 (cluster #1 Of 3), Other | Other | 27 | 0.25 | Binding ≤ 10μM |
Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 933 | 0.20 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
Z104304 | Z104304 | Adrenergic Receptor Alpha-1 | 27 | 0.25 | Binding ≤ 1μM |
ADA2A_RAT | P22909 | Alpha-2a Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 1μM |
ADA2B_RAT | P19328 | Alpha-2b Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 1μM |
ADA2C_RAT | P22086 | Alpha-2c Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 1μM |
Z104304 | Z104304 | Adrenergic Receptor Alpha-1 | 27 | 0.25 | Binding ≤ 10μM |
ADA2A_RAT | P22909 | Alpha-2a Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 10μM |
ADA2B_RAT | P19328 | Alpha-2b Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 10μM |
ADA2C_RAT | P22086 | Alpha-2c Adrenergic Receptor, Rat | 3.7 | 0.27 | Binding ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 1010 | 0.20 | Functional ≤ 10μM |
CP3A4_HUMAN | P08684 | Cytochrome P450 3A4, Human | 2999.16252 | 0.18 | ADME/T ≤ 10μM |
Description | Species |
---|---|
Adrenaline signalling through Alpha-2 adrenergic receptor | |
Adrenaline,noradrenaline inhibits insulin secretion | |
Adrenoceptors | |
Aflatoxin activation and detoxification | |
G alpha (i) signalling events | |
G alpha (z) signalling events | |
Xenobiotics |